CA
NZ
UK
AU
IND
US
…
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Forte Biosciences is a clinical-stage biotechnology company developing microbiome-targeted topical therapies for dermatology and hair disorders. Its long-term growth may be supported by progressing clinical programs, potential regulatory approvals, strategic partnerships or licensing, and broader market interest in microbiome-based approaches for high‑prevalence skin conditions. Investors may find the company attractive because it appears positioned to deliver program-specific clinical catalysts and commercial upside if its differentiated mechanism translates into safe, effective treatments.
The primary investment risks are clinical and regulatory setbacks, the likely need for additional financing to complete development and commercial launch, and substantial competition from established dermatology companies and other microbiome-focused developers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -68.34M | -35.48M | -31.48M | -13.88M | -21.71M |
| Net income | -69.38M | -35.48M | -31.48M | -13.86M | -21.71M |
| Selling general administrative | 12.41M | 15.41M | 10.62M | 8.30M | 7.63M |
| Selling and marketing expenses | - | - | 0.01M | - | - |
| Gross profit | -0.06M | -0.04M | -0.01M | - | - |
| Reconciled depreciation | 0.06M | 0.04M | 0.00M | 0.00M | 0.04M |
| Ebit | -70.66M | -35.48M | -32.49M | -13.90M | -21.49M |
| Ebitda | -70.59M | -35.44M | -32.48M | -13.90M | -21.45M |
| Depreciation and amortization | 0.06M | 0.04M | 0.01M | - | 0.04M |
| Operating income | -70.66M | -36.60M | -32.49M | -13.90M | -21.49M |
| Other operating expenses | 70.66M | 36.60M | 32.49M | 13.90M | 21.49M |
| Interest expense | - | - | - | 0.02M | 0.22M |
| Tax provision | 1.04M | - | - | - | - |
| Interest income | 2.71M | 1.31M | 1.12M | - | - |
| Net interest income | 2.71M | 1.31M | 1.12M | - | - |
| Income tax expense | 1.04M | -35.48M | - | -0.02M | 0.22M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 70.66M | 36.56M | 32.48M | 13.90M | 21.49M |
| Cost of revenue | 0.06M | 0.04M | 0.01M | - | - |
| Total other income expense net | 2.32M | 1.12M | 1.01M | 0.02M | -0.22M |
| Net income from continuing ops | -69.38M | -35.48M | -30.48M | -13.88M | -21.71M |
| Net income applicable to common shares | - | - | - | -13.88M | -21.71M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 82.78M | 61.56M | 38.98M | 42.00M | 43.31M |
| Other current assets | 2.81M | 2.98M | 1.20M | 0.07M | 0.09M |
| Total liab | 21.79M | 9.08M | 3.67M | 3.18M | 1.76M |
| Total stockholder equity | 60.99M | 52.48M | 35.31M | 38.82M | 41.55M |
| Deferred long term liab | - | - | - | - | 0.11M |
| Other current liab | 9.72M | 4.20M | 2.24M | 2.03M | 0.81M |
| Common stock | 0.01M | 0.01M | 0.04M | 0.02M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.04M | 0.02M | 0.01M |
| Retained earnings | -223.37M | -154.00M | -118.52M | -87.04M | -73.17M |
| Other assets | - | - | 0.00M | - | 0.79M |
| Cash | 76.96M | 22.24M | 11.96M | 41.10M | 42.04M |
| Total current liabilities | 20.75M | 9.08M | 3.67M | 3.18M | 1.76M |
| Net debt | -76.96M | -22.24M | -11.96M | -41.10M | -42.04M |
| Other stockholder equity | 284.35M | 206.46M | 153.79M | 125.84M | 114.70M |
| Total current assets | 80.59M | 61.35M | 38.33M | 41.51M | 42.52M |
| Net tangible assets | - | - | - | 38.82M | 41.55M |
| Short term investments | 0.00M | 36.12M | 25.16M | - | - |
| Net receivables | 0.82M | - | - | - | - |
| Accounts payable | 9.99M | 4.88M | 1.42M | 1.15M | 0.95M |
| Accumulated other comprehensive income | 0.00M | 0.01M | 0.00M | - | -43.31M |
| Non currrent assets other | 2.06M | 0.14M | 0.54M | 0.49M | 0.79M |
| Non current assets total | 2.19M | 0.21M | 0.65M | 0.49M | 0.79M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 36.35M | -35.99M | 0.05M | - | 0.00M |
| Change to liabilities | - | - | - | 0.21M | -0.29M |
| Total cashflows from investing activities | 36.23M | -35.99M | 0.05M | - | - |
| Total cash from financing activities | 69.36M | 51.86M | 24.68M | 7.24M | -0.04M |
| Change to operating activities | - | - | - | - | 1.01M |
| Net income | -69.38M | -35.48M | -31.48M | -13.88M | -21.71M |
| Change in cash | 54.71M | -14.88M | -3.98M | -0.94M | -16.72M |
| Begin period cash flow | 22.24M | 37.12M | 41.10M | 42.04M | 58.77M |
| End period cash flow | 76.96M | 22.24M | 37.12M | 41.10M | 42.04M |
| Total cash from operating activities | -50.88M | -30.75M | -28.71M | -8.19M | -16.68M |
| Issuance of capital stock | 75.00M | 53.00M | 24.74M | 7.23M | 0.00M |
| Depreciation | 0.06M | 0.04M | 0.01M | 0.00M | 0.04M |
| Sale purchase of stock | 0.00M | -0.00M | -0.00M | - | - |
| Other cashflows from financing activities | -7.47M | -1.14M | -0.03M | 0.01M | -0.04M |
| Change to netincome | - | - | - | - | 4.28M |
| Capital expenditures | 0.12M | 0.04M | 0.09M | 0.00M | 0.06M |
| Change in working capital | 11.37M | 1.76M | -0.39M | 1.68M | 0.72M |
| Stock based compensation | 6.26M | 3.10M | 3.28M | 4.01M | 4.21M |
| Other non cash items | -0.24M | -0.16M | -0.13M | - | 0.06M |
| Free cash flow | -51.00M | -30.78M | -28.79M | -8.19M | -16.68M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-1.88 4.46% |
40.30 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.54 1.19% |
542.50 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-27.77 2.98% |
902.90 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
3060 Pegasus Park Drive, Dallas, TX, United States, 75247
310 618 6994
19
| Name | Title | Year Born |
|---|---|---|
| Dr. Paul A. Wagner Ph.D. | CEO & Chairman | 1970 |
| Mr. Antony A. Riley CPA | Chief Financial Officer | 1967 |
| Dr. Hubert C. Chen M.D. | Pres & Chief Scientific Officer | 1969 |
| Mr. Christopher Roenfeldt | Chief Operating Officer | NA |
| Mr. Steven Ruhl | Chief Technical Officer | 1957 |
| Dr. Paul A. Wagner Ph.D. | CEO, President & Chairman | 1970 |
| Dr. Barbara K. Finck M.D. | Chief Medical Clinician & Director | 1947 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.55%
Communication Services
-0.77%
Consumer Cyclical
-1.05%
Consumer Defensive
-0.33%
Energy
-2.55%
Financial Services
-1.62%
Financials
-0.80%
Healthcare
-2.85%
Industrials
-2.47%
Real Estate
-0.85%
Technology
-5.38%
Utilities
-0.83%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+31.04%
Please wait processing your request...